Jayson Dallas
Director/Miembro de la Junta en GALECTO, INC. .
Fortuna: - $ al 30/04/2024
Cargos activos de Jayson Dallas
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
GALECTO, INC. | Director/Miembro de la Junta | 19/11/2020 | - |
Independent Dir/Board Member | 19/11/2020 | - | |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Director Ejecutivo | 29/06/2023 | - |
Presidente | 01/04/2021 | 15/11/2023 |
Historial de carrera de Jayson Dallas
Antiguos cargos conocidos de Jayson Dallas.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ARENA PHARMACEUTICALS | Director/Miembro de la Junta | 14/02/2017 | 11/03/2022 |
Independent Dir/Board Member | 14/02/2017 | 11/03/2022 | |
AIMMUNE THERAPEUTICS, INC. | Director/Miembro de la Junta | 19/06/2018 | 01/10/2020 |
Director Ejecutivo | 19/06/2018 | 01/10/2020 | |
Presidente | 19/06/2018 | 01/10/2020 | |
ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 03/08/2015 | 18/06/2018 |
Roche Holding (UK) Ltd.
Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Corporate Officer/Principal | 01/07/2012 | 01/07/2015 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/05/2010 | 01/12/2012 |
Formación de Jayson Dallas.
Knox College | Undergraduate Degree |
University of the Witwatersrand | Doctorate Degree |
Ashridge Business School | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 8 |
Reino Unido | 3 |
Sudafrica | 2 |
Operativa
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
GALECTO, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Roche Holding (UK) Ltd.
Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Health Technology |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Health Technology |
- Bolsa de valores
- Insiders
- Jayson Dallas
- Experiencia